Criner GJ, et al. - In the GALATHEA and TERRANOVA trials, researchers tested the effectiveness and safety of benralizumab for the prevention of exacerbations in patients with moderate to very severe chronic obstructive pulmonary disease (COPD). Patients with COPD (at a ratio of approximately 2:1 on the basis of eosinophil count [≥ 220 per cubic millimeter vs < 220 per cubic millimeter]) who had frequent exacerbations despite receiving guideline-based inhaled treatment were recruited. Participants in the study were randomized to receive benralizumab (30 or 100 mg in GALATHEA; 10, 30, or 100 mg in TERRANOVA) every 8 weeks (every 4 weeks for the first three doses) or placebo. Add-on benralizumab was not linked to a lower annualized rate of COPD exacerbations than placebo in patients with moderate to very severe COPD, a history of frequent moderate or severe exacerbations, and blood eosinophil counts of ≥ 220 per cubic millimeter. Adverse event types and frequencies were similar for benralizumab and placebo.